What Is AOD-9604?
AOD-9604, also designated as tyr-hGH fragment 177-191, is a 15-amino acid synthetic peptide derived from the C-terminal end of human growth hormone (hGH). The parent compound corresponds to amino acids 177 to 191 of the 191-amino acid hGH sequence, and the synthetic version incorporates a tyrosine residue at the N-terminus to facilitate radiolabeling and improve metabolic stability. Its development was pioneered by researchers at Metabolic Pharmaceuticals in Australia during the late 1990s and early 2000s.
The fundamental rational for developing AOD-9604 was to isolate the lipolytic (fat-burning) activity of growth hormone from its growth-promoting activity. Full-length hGH has multiple biological effects including linear bone growth, muscle hypertrophy, insulin resistance, and lipolysis. The hypothesis was that the C-terminal region of hGH contained a discrete domain responsible for its fat metabolism effects, and that a peptide corresponding to this domain would selectively activate lipolysis without the endocrine and metabolic side effects of complete growth hormone.
The hGH 177–191 Fragment and Its Properties
The identification of the 177-191 region as containing lipolytic activity was based on structure-activity relationship studies mapping different hGH fragments against their fat-burning capacity in adipocyte models. This region of hGH had been previously identified as important for receptor binding affinity and adipogenic signaling, though its exact structural relationship to hGH receptor engagement was complex.
Unlike full-length hGH, AOD-9604 does not appear to bind significantly to the classical hGH receptor and does not stimulate IGF-1 production — the primary mediator of hGH’s anabolic and growth-promoting effects. This dissociation of IGF-1 stimulation from lipolytic activity was a key design criterion and was confirmed in multiple in vitro and animal studies, establishing AOD-9604’s metabolically selective profile.
Lipolysis Mechanisms
Research into the mechanism by which AOD-9604 stimulates lipolysis has identified activation of beta-3 adrenergic receptors and downstream cyclic AMP (cAMP)-mediated signaling as important pathways. Unlike the classic hGH lipolytic mechanism which generally operates through hGH receptor engagement, AOD-9604 appears to stimulate lipolysis through a pathway more analogous to beta-adrenergic receptor agonism, increasing intracellular cAMP, activating protein kinase A (PKA), and promoting hormone-sensitive lipase (HSL) activity to hydrolyze stored triglycerides.
In vitro studies using human and animal fat cell preparations demonstrated dose-dependent increases in glycerol release (a measure of lipolysis) following AOD-9604 treatment. Animal studies comparing AOD-9604 to full-length hGH showed similar magnitudes of lipolytic response in adipose tissue, validating the fragment’s fat-metabolizing capability. Importantly, AOD-9604 did not produce the hyperglycemia associated with full-length hGH, which causes clinically significant insulin resistance.
Clinical Trials History
AOD-9604 underwent a relatively extensive clinical development program for an anti-obesity peptide. Metabolic Pharmaceuticals conducted Phase I safety trials that confirmed good tolerability and the absence of significant glucose metabolism perturbation — one of the primary safety concerns for any hGH-derived compound.
Phase II trials were conducted to evaluate efficacy in obesity. A notable clinical study by Heffernan et al. examined the effects of oral AOD-9604 in obese subjects over multiple weeks, measuring body weight, fat mass by DEXA scanning, and metabolic parameters. Results showed a trend toward greater fat loss in the AOD-9604-treated group compared to placebo, though statistical significance was not consistently achieved across all endpoints and time points.
A Phase IIb clinical trial enrolled several hundred obese subjects and evaluated multiple doses of oral AOD-9604 over 24 weeks. This larger trial, results from which were published in the scientific literature and summarized in regulatory documents, demonstrated modest weight loss versus placebo but did not achieve the predefined efficacy thresholds required to advance to Phase III. The clinical development program for obesity was subsequently discontinued, primarily due to insufficient efficacy signal in the Phase IIb data.
Importantly, AOD-9604 received GRAS (Generally Recognized as Safe) status from the U.S. Food and Drug Administration for use as a food ingredient — a recognition of its favorable safety profile even in the absence of drug approval.
Cartilage Repair Research
Following the discontinuation of the obesity program, research interest in AOD-9604 pivoted to joint and cartilage repair applications. Studies demonstrated that AOD-9604 could stimulate the synthesis of proteoglycans in cartilage tissue explants and promote chondrocyte differentiation from mesenchymal stem cells. These findings suggested potential utility in osteoarthritis — a condition characterized by progressive articular cartilage degradation.
Animal studies in rodent models of osteoarthritis reported reduced cartilage degradation and improved histological scores in joints treated with AOD-9604 compared to controls. The mechanism proposed involves interaction with the receptor for advanced glycation end-products (RAGE) and downstream modulation of inflammatory and matrix remodeling pathways in chondrocytes. Clinical research in osteoarthritis has been initiated, with preliminary results reported at conferences suggesting potential benefit, though peer-reviewed clinical trial data in this indication remains limited at the time of writing.
Comparison to Full-Length hGH
The comparative biology of AOD-9604 versus full-length hGH illuminates both the successes and limitations of the fragment approach. AOD-9604 successfully recapitulates hGH’s lipolytic activity while avoiding growth stimulation, IGF-1 induction, and insulin resistance. However, the magnitude of fat loss achieved with AOD-9604 in clinical trials was modest compared to what is observed with supraphysiological hGH doses in research settings, suggesting that full-length hGH’s lipolytic potency may depend partly on receptor interactions not captured by the 177-191 fragment.
Regulatory Status
AOD-9604 is not approved as a pharmaceutical drug by the FDA, EMA, or TGA for any indication. In Australia, the TGA classified it as a Schedule 4 prescription medicine, with it having previously been briefly available through compounding pharmacies before regulatory reclassification. It is not approved for human administration in most jurisdictions and is classified as a research compound. In 2015, the World Anti-Doping Agency (WADA) removed AOD-9604 from its prohibited list after reviewing evidence that it did not significantly affect IGF-1 levels or provide meaningful performance-enhancing effects beyond its potential fat-loss activity.
References
- Heffernan M, Summers RJ, Thorburn A, et al. “The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.” Endocrinology. 2001;142(12):5182–5189.
- Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. “Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.” Hormone Research. 2000;53(6):274–278.
- Stier H, Vos E, Kenyon NS. “Safety and tolerability of AOD9604, a synthetic fragment of human growth hormone, in young healthy adults.” Clinical and Experimental Pharmacology and Physiology. 2012;39:1.e1–e12.
- Denko CW, Boja B, Moskowitz RW. “Growth promoting peptides in osteoarthritis and diffuse idiopathic skeletal hyperostosis—insulin, insulin-like growth factor-I, growth hormone.” Journal of Rheumatology. 1994;21(9):1725–1730.
- Kwon DR, Park GY, Lee SC. “The effects of intraarticular hyaluronic acid injection in combination with the AOD9604 peptide on cartilage degradation in a rat model of collagenase-induced osteoarthritis.” PLoS One. 2019;14(11):e0224477.